Show Summary Details
Page of

Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial 

Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial
Chapter:
Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial
Author(s):

Sarah A. Mulukutla

DOI:
10.1093/med/9780199377527.003.0012
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 September 2019

This chapter provides a summary of a landmark study in multiple sclerosis. Is interferon beta-1a therapy beneficial when started soon after a patient’s first clinical demyelinating event? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients at high risk for developing MS, early treatment with interferon beta-1a decreased the proportion of patients who converted to clinically definite disease. Initiating treatment at first demyelinating event also reduced the accumulation rate of new MRI-detected white matter lesions during drug exposure. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.